BEVERLY HILLS, Calif., March 20, 2014 /PRNewswire/ -- Life Stem Genetics, Inc. (LIFS), an emerging innovator in the advancement of Adult Stem Cell therapies, today announced the appointment of Dr. Vino Padayachee, a well-known family physician/anesthetist, as Director and Chairman of the Board of Directors of the company. Dr. Padayachee has been actively involved in the Saskatchewan Medical Association as a member of the Representative Assembly, the Board of Directors, and the executive. He served as Chief of Staff of St. Joseph's Hospital in Estevan, Saskatchewan, from 1998 to 2009, as Chief of Staff of South East Health District from 1999 to 2004, and as Chief of Staff of Sun Country Health Region from 2004 to 2008. He was the first Clinical Chair for the Health Quality Council Chronic Disease Management Collaborative from 2005 to 2007. Dr. Padayachee served as President of the Saskatchewan Medical Association in 2006-2007 and as CEO of the Saskatchewan Medical Association from 2011 to February 2014.
Dr. Padayachee commented, "Adult Stem Cells, particularly mesenchymal cells which can differentiate into a variety of tissues, hold immense promise in the treatment of a wide range of conditions. Many patients, including those with autoimmune diseases such as multiple sclerosis, type 1 diabetes, and rheumatoid arthritis, as well as patients with heart disease, spinal cord trauma, and orthopedic injuries should see benefits from this promising new form of therapy. Life Stem's focus on mesenchymal cell harvesting and the advanced medical applications therein represent a robust market segment that should continue to produce leading-edge advancements in these critical treatment areas over the coming years and decades. I am ecstatic to be joining Life Stem Genetics as Director and Chairman of the Board of Directors, and I look forward to working with the company's dedicated personnel and advisors on the continued advancement of Adult Stem Cell therapies for the benefit of all."
Gloria Simov, president and CEO of Life Stem Genetics, added, "Dr. Padayachee, in his position as President and CEO of the Saskatchewan Medical Association, developed contacts with leaders in the health/medical field throughout North America. Dr. Paydayachee's demonstrated leadership skills together with his impressive medical and administrative background provides our company with a powerful new voice in advancing the potential of Adult Stem Cell therapies. Dr. Padayachee exudes a keen interest in the areas of quality of health improvement where advanced Adult Stem Cell (ASC) therapies have the potential to revolutionize treatment options for patients. We are extremely excited about his forthcoming contributions to our company as Director and Chairman of the Board of Directors. Regenerative medicine is projected to be a $35 billion industry by 2018. We are in the process of updating our corporate growth agenda for 2014 to enable us to play a significant part in that industry and will be presenting that update to our shareholders and the investing community in the near future."
About Dr. Vino Padayachee
Dr. Padayachee began his medical career in South Africa, where he obtained his medical degree from the University of Natal. After graduating, he worked in teaching hospitals attached to the university where he developed a broad range of expertise including pediatrics, surgery and trauma, and obstetrics, including special training in cardiology. During that time, he managed a coronary care unit and obtained a diploma in anesthesiology. In 1992, Dr. Padayachee moved to Canada, along with his wife, Dr. Diane Naidu, to settle in Estevan, Saskatchewan, where he practiced as a general practitioner anesthetist. Dr. Padayachee has a dedicated interest in quality improvement, and, in response to the increasing prevalence of asthma in southern Saskatchewan, he helped establish an asthma clinic in 2003 and was also involved with the Heart to Heart Coronary Heart Disease Secondary Prevention Program in Estevan. Dr. Padayachee served as chief of staff of St. Joseph's Hospital in Estevan, Saskatchewan, and the Sun Country Health Region. He also served as clinical chair for the Health Quality Council Chronic Disease Management Collaborative from 2005 to 2007. Dr. Padayachee has been actively involved in the Saskatchewan Medical Association as a member of the Representative Authority, the Board of Directors, and the executive. Dr. Padayachee served as President of the Saskatchewan Medical Association from 2006 to 2007 and as CEO from 2011 to February 2014.
About Life Stem Genetics
Life Stem Genetics, symbol: LIFS, is a fully reporting, audited public company. LIFS is a progressive healthcare company focused on Adult Stem Cell (ASC) healing therapies and stem cell related products. Stem cells have been utilized in the successful treatment of a variety of ailments. Today, advanced ASC therapies are being offered to patients as an efficient and painless alternative treatment for a wide range of ailments including, but not limited to, orthopedic injuries, neurological disorders such as Parkinson's and Alzheimer's, cancer, arthritis, diabetes, multiple sclerosis, as well as age management. Adult Stem Cell therapies are experiencing some of the best results in the health care industry in helping to repair or reprogram damaged or diseased tissues and organs. ASC treatments have been performed on some of the top names in PGA golf, NFL football, NBA basketball, and Major League Baseball. LSG will offer treatments through a series of affiliate doctors and medical clinics in the U.S., Canada, South America, Europe, and the Middle East.
Contrarian Press, an established publisher, has been engaged by Life Stem Genetics to assist with patient generation and those who may be interested in learning more about the company and its securities. Updated disclaimer and disclosure information is available at the publisher's website and at the following link: http://www.contrarianwealthcoalition.com/guide/LIFS.pdf
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may", "could", "estimates", "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and the Company's future performance, operations, and products. Such statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to differ materially from the results expressed or implied by such statements. Such risks and uncertainties include, without limitation, market acceptance of the Company's stem cell therapy treatment program; the Company's compliance with applicable statutes and regulations: the Company's reliance on third-party contractors to provide suitable treatment facilities; the Company's ability to expand its network of participating clinics and doctors; the Company's ability to develop an effective marketing strategy; the Company's ability to control and reduce advertising and marketing costs; the Company's ability to develop and increase awareness of its brand; the Company's ability to protect its trademarks; and the success of the Company's marketing focus to patients, doctors and clinics. For a discussion of these and other risks and uncertainties see "Risk Factors" and "Description of Business" in the Company's public filings with the SEC. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
SOURCE Life Stem Genetics, Inc.